Mass Spectrometry Market worth $10.78 billion by 2031
The report "Mass Spectrometry Market by Product [Instrument (Triple Quadrupole, Q-TOF, FTMS, Quadrupole, TOF), Software, Services], Inlet Type (LC-MS, GC-MS, ICP-MS, Other Inlet Types), Application (Omics, Drug Discovery, Food, Environmental), End User (Pharma, Biotech) - Global Forecast to 2031"The mass spectrometry market is expected to grow from USD 7.07 billion in 2026 to USD 10.78 billion by 2031, at a CAGR of 8.8% during this period.
Browse 250 market data Tables and 50 Figures spread through 350 Pages and in-depth TOC on "Mass Spectrometry Market by Product [Instrument (Triple Quadrupole, Q-TOF, FTMS, Quadrupole, TOF), Software, Services], Inlet Type (LC-MS, GC-MS, ICP-MS, Other Inlet Types), Application (Omics, Drug Discovery, Food, Environmental), End User (Pharma, Biotech) - Global Forecast to 2031"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/mass-spectrometry-market-437.html
The market is the transition from traditional batch-based quality testing toward real-time release testing (RTRT) and continuous manufacturing in pharmaceutical and food production environments. Pharmaceutical manufacturers are increasingly integrating high-resolution LC-MS/MS and hybrid MS systems directly into manufacturing workflows for inline impurity profiling, nitrosamine detection, extractables & leachable analysis, and biologic process monitoring. Simultaneously, food and beverage manufacturers are adopting ultra-sensitive mass spectrometry platforms for multi-residue pesticide screening, PFAS detection, authenticity verification, and contaminant fingerprinting as global food safety regulations become stricter. This shift is creating demand for automated, high-throughput, AI-enabled mass spectrometry systems capable of handling large-scale industrial quality control operations with minimal manual intervention.
Another trend reshaping the market is the emergence of CRO-centered decentralized bioanalytical ecosystems supported by cloud-connected mass spectrometry infrastructure. Rather than operating as standalone testing facilities, leading CROs are now building globally integrated bioanalytical networks equipped with standardized Orbitrap, Q-TOF, and triple quadrupole MS platforms to support multinational clinical trials and decentralized drug development programs. Pharmaceutical sponsors are increasingly transferring not only sample analysis but also assay development, biomarker validation, and regulated pharmacokinetic workflows to CROs, creating recurring instrument utilization cycles and long-term service contracts. Additionally, CROs are investing heavily in AI-assisted spectral interpretation, automated sample preparation robotics, and digital laboratory management systems to reduce turnaround times for high-volume clinical studies. This evolution is transforming mass spectrometry from a laboratory-based analytical tool into a scalable data-driven infrastructure platform supporting global outsourced drug development and precision medicine programs.
The instruments segment dominated the overall market in 2025.
Based on product, the mass spectrometry market is segmented into instruments, software, and services. The instruments segment accounts for the largest share of the mass spectrometry market. Hospitals and large diagnostic networks are increasingly deploying automated benchtop hybrid MS systems for decentralized high-volume clinical testing, including endocrinology, therapeutic drug monitoring, toxicology, steroid profiling, and newborn screening. Unlike earlier adoption cycles focused mainly on research laboratories, current purchasing decisions are being driven by long-term assay menu expansion strategies and laboratory consolidation initiatives. Vendors are therefore launching compact, walkaway automation-enabled hybrid MS systems with pre-validated clinical workflows, integrated middleware, AI-assisted spectral interpretation, and simplified operation layers designed specifically for routine clinical laboratory environments. This is significantly expanding adoption among mid-sized hospitals and regional diagnostic laboratories that previously depended on immunoassays or outsourced testing services.
Another high-impact trend reshaping the market is the emergence of lifecycle-driven replacement economics and “clinical insourcing” strategies across healthcare systems. Large hospitals, reference laboratories, and integrated delivery networks are increasingly internalizing high-value mass spectrometry testing to reduce turnaround time, improve reimbursement capture, and strengthen data ownership for precision medicine programs. This shift is accelerating demand for next-generation hybrid MS platforms with higher multiplexing capability, ultra-fast polarity switching, and cloud-connected remote diagnostics that support continuous assay upgrades without replacing the full instrument stack.
The LC-MS segment dominated the overall mass spectrometry market in 2025.
By inlet type, the mass spectrometry market is categorized into LC-MS, GC-MS, ICP-MS, and other techniques. The advent of new applications of LC-MS for testing emerging contaminants from third-party testing service providers and labs has increased in the last three years. All these conditions have helped LC-MS to acquire a major share in the mass spectrometry market. The use of LC-MS has expanded over the years as it offers both selectivity and specificity in analysis. With advances in mass spectrometry, the sensitivity and accuracy of this technique have further increased, allowing for the detection and identification of low-level analytes in complex sample matrices. Liquid chromatography (LC) is a technique widely used to separate compounds from a sample before analysis and is frequently coupled to mass spectrometry.
All these factors have helped LC-MS to acquire a major share in the mass spectrometry market.
Some of the leading players in this market include Agilent Technologies, Inc. (US), Thermo Fisher Scientific, Inc. (US), Danaher Corporation (US), Waters Corporation (US), Bruker Corporation (US), Shimadzu Corporation (Japan), PerkinElmer, Inc (US) Jeol, Ltd (Japan), Jasco (Japan), Teledyne Technologies Incorporated (US), and MKS Instruments (US), and others.
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Mass Spectrometry Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
